Autoantibodies against type 1 interferons linked to higher susceptibility to viral disease

In­cyte ex­pects its atopic der­mati­tis and vi­tili­go treat­ment Opzelu­ra to be a “key con­trib­u­tor” to growth in 2024 af­ter sales jumped 78% in the fourth

Law­mak­ers have spent the spring and sum­mer chip­ping away at re­forms to phar­ma­cy ben­e­fit man­agers — the mid­dle­men en­ti­ties that in­sur­ance com­pa­nies hire to ne­go­ti­ate